Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

676504 VEGFR Tyrosine Kinase Inhibitor VI, AAL-993 - CAS 269390-77-4 - Calbiochem

The VEGFR Tyrosine Kinse Inhibitor VI, ALL-993, also referenced under CAS 269390-77-4, controls the biological activity of VEGFR Tyrosine Kinase. This small molecule/inhibitor is primarily used for Cancer applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII

View Products on Sigmaaldrich.com
676504
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
269390-77-4C₂₀H₁₆F₃N₃O

Products

Catalogue NumberPackaging Qty/Pack
676504-10MG Glass bottle 10 mg
Description
OverviewA cell-permeable anthranilamide that acts as a potent VEGFR inhibitor (IC50 = 130, 23, and 18 nM against VEGFR-1, -2, and -3, respectively; IC50 = 1.24 nM against VEGF-induced human VEGFR-2 phosphorylation in CHO cells) by targeting the ATP-binding site of VEGFR in its inactive "DFG-out" conformation and effectively suppresses tumor growths (50 to 100 mg/kg; p.o.) via its anti-angiogenesis activity in mice and rats in vivo, while inhibiting c-kit, CSF-1R/c-Fms, PDGFR-β, and c-Abl only at higher concentrations (IC50 = 236, 380, 640, and 2820 nM, respectively). AAL933 and two other VEGFR inhibitors, KRN633 and SU5416 (Cat. No. 676487), are also shown to inhibit hypoxia-induced HIF-1α expression (by <90% at 30 µM) and transcription activation. Unlike KRN633 and SU5416, AAL933 prevents only hypoxia-induced Erk, but not Akt, phosphorylation in HeLa cells.
Catalogue Number676504
Brand Family Calbiochem®
Synonyms2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII
References
ReferencesBan, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.
Product Information
CAS number269390-77-4
FormOff-white powder
Hill FormulaC₂₀H₁₆F₃N₃O
Chemical formulaC₂₀H₁₆F₃N₃O
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥97% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Regulatory Review
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
676504-10MG 04055977260533

Documentation

VEGFR Tyrosine Kinase Inhibitor VI, AAL-993 - CAS 269390-77-4 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Ban, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.

Brochure

Title
New Products: Volume 3, 2012
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision04-June-2012 JSW
Synonyms2-((4-Pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide, ZK260253, AAL993, VEGFR2 Kinase Inhibitor XXXIII, VEGFR1 Kinase Inhibitor VIII, VEGFR3 Kinase Inhibitor VII, PDGFR Tyrosine Kinase Inhibitor XXIII
DescriptionA cell-permeable anthranilamide that acts as a potent VEGFR inhibitor (IC50 = 130, 23, and 18 nM against VEGFR-1, -2, and -3, respectively; IC50 = 1.24 nM against VEGF-induced human VEGFR-2 phosphorylation in CHO cells) by targeting the ATP-binding site of VEGFR in its inactive "DFG-out" conformation, while inhibiting c-kit, CSF-1R/c-Fms, PDGFR-β, and c-Abl only at higher concentrations (IC50 = 236, 380, 640, and 2820 nM, respectively) and displaying little or no activity against EGFR/HER-1/ErbB (IC50 = 10.4 µM) and six other kinases (IC50 ≥10 µM). Reported to be orally available in mice (Conc. in plasma = 9.5, 4.7, 1.5, and 1.1 µM, respectively, 0.5 h, 1 h, 1.5 h, and 2 h after p.o. dosage of 50 mg/kg), rats, and dogs, and effectively suppress tumor growths (50 to 100 mg/kg; p.o.) via its anti-angiogenesis activity in various cancer models in vivo, including murine melanoma B16-BL6, rat mammary adenocarcinoma BN472, as well as human prostate cancer DU145-grafted mice in vivo. AAL933 and two other VEGFR inhibitors, KRN633 and SU5416 (Cat. No. 676487), are also shown to inhibit hypoxia- (1% O2) induced HIF-1α expression (by <90% at 30 µM) and transcription activation (IC50 = 6.53, 3.79, and 8.24 µM, respectively, by AAL933, KRN633, and SU5416 in HeLa-HRE-Luc reporter assays). However, unlike KRN633 and SU5416, AAL933 prevents only hypoxia-induced Erk, but not Akt, phosphorylation in HeLa cells.
FormOff-white powder
Intert gas (Yes/No) Packaged under inert gas
CAS number269390-77-4
Chemical formulaC₂₀H₁₆F₃N₃O
Structure formulaStructure formula
Purity≥97% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Regulatory Review
ReferencesBan, H.S., et al. 2010. Cancer Lett. 296, 17; Manley, P.W., et al. 2004. Biochim. Biophys. Acta 1697, 17; Manley, P.W., et al. 2002. J. Med. Chem. 45, 5687.